Investor mix
5 investors on record; lead investors include Xerys.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 80% |
| Private equity | 1 | 20% |
Developing Tau-protein targeted small molecule drugs for neurodegenerative diseases
5 investors on record; lead investors include Xerys.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 80% |
| Private equity | 1 | 20% |